Therakos Logo
Languages:
Therakos e-learning platform

The Therakos Institute

WELCOME TO OUR EDUCATIONAL PLATFORM

At the Therakos Institute, our primary goal is to advance knowledge and understanding around ECP immunomodulation. We have forged valuable partnerships with leading experts from around the world, regularly

bringing our best and brightest together to provide accessible education to HCPs. Through these collaborations, we aim to build a better future for patients.

Our Educational Offer

CENTRES OF EXCELLENCE
PROGRAMME

We partner with several European Centres of Excellence (CoE) to provide high-quality professional education to committed healthcare professionals.

FIND OUT MORE

WEBINARS

Up-to-date coverage of a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

FIND OUT MORE

SPEAKER MEETINGS

The latest scientific knowledge and advancements in ECP brought to life in conversation by major thought leaders.

FIND OUT MORE

SYMPOSIA

Major thought leaders present on specific topics on the latest in ECP Immunomodulation – guaranteed to be both stimulating and informative.

FIND OUT MORE

ASK THE EXPERT

Private, one-to-one sessions with leading experts in their respective fields of relevance to ECP and its clinical applications.

BOOK YOUR SESSION

Developing Leadership
in Healthcare

An SDA Bocconi course.

Sponsored by Mallinckrodt.

FIND OUT MORE

Brilliant Speakers

Our communication course dedicated to bringing
our leaders into the new era of engagement.

FIND OUT MORE

Our Centres of Excellence

Discover all our Centres of Excellence and find one close to you

Our Webinars

Watch our on demand webinars and sign up to our next live dates

Our Symposia

See the full calendar of our SYMPOSIA

Our Speaker Meetings

See the full calendar of our speaker meetings

Ask the Expert

Choose your topic and book your one-to-one session with a leading industry expert

CoE COURSES

OUR
WEBINARS

Symposia

SPEAKER
MEETINGS

NEXT EVENTS ACROSS ALL CENTRES
OF EXCELLENCE

Event postponed – a new date will be available soon

Read more

There are no courses available at the moment for this center, but we do update our courses regularly. Check again soon to make sure you don't miss out.

NEXT EVENTS ACROSS ALL CENTRES
OF EXCELLENCE

Single event

Overlapping events

You are leaving the THERAKOS.EU website.
Therakos does not review or control the content of non-Therakos websites, and this hyperlink does not constitute an endorsement by Therakos of the site’s content. Therakos privacy procedures do not apply to the owners of a non-Therakos website.

Important Safety Information
For the TherakosTM Photopheresis
Procedure

Indications

The THERAKOSTM CELLEXTM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOSTM Photopheresis is contraindicated in:

  • Patients possessing a specific history of a light sensitive disease.
  • Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm3.
  • Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOSTM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

  • Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
  • Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
  • When prescribing and administering THERAKOSTM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

  • Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
  • Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
  • Treatment frequency exceeding labelling recommendations may result in anaemia.
  • Venous access carries a small risk of infection and pain.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

  • Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
  • Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
  • Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
  • Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

  • Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
  • Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
  • Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
  • Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

This website is not intended for healthcare professionals based in US, France and Canada.

Please verify your status below.

I am a healthcare professional and

I am eligible to access this part of the website

I am not a healthcare professional.

I would like to return to the homepage

This website is not intended for residents
based in the US, France or Canada.

PLEASE CLICK HERE TO ENTER

If you are a French resident, please visit www.therakos.fr

The winner of the 2021 ECP Immunomodulation Investigator Award was submitted by Dr Etienne Daguindau from the RIGHT institute (UMR1098) in collaboration with the University Hospital of Besançon, France.

Full details are available on our press release page.

The 2022 edition will open later this year. Visit us again for more details.

Copy the link to share with the HCP by clicking on the button below

 
THANK YOU FOR YOUR MESSAGE
We will take care of your request and get in contact with you soon
 
THANK YOU FOR YOUR APPLICATION
We can confirm we have received your submission.
 
AUTHORISATION

The Therakos e-learning platform wants to access the following information:

Your basic public profile
Your public email address

Please click the below button to authorise it

WELCOME TO THERAKOS.EU MY AREA
Forgot your password? Click Here
Not yet registered?
WELCOME TO THERAKOS.EU MY AREA
Forgot your password?